Imaging Through the Pipeline

Featured In: Bioscience Technology Magazine | Life Science Pulse Newsletter | Cancer | Pharma | Imaging | Cameras | Image Analysis | Image Analysis and Image Processing Software | Lasers

Monday, June 15, 2024

newsvine diigo google
slashdot
Share
Loading...
The evolution of live animal imaging technology has helped researchers get a better picture of the drug research process, from target identification to pharmacokinetic studies.




Prostate tumor visualized in 3D reconstructions for precise quantitation and localization. (Source: Caliper Life Sciences)

As animal imaging techniques evolve from providing information about anatomy to providing molecular-level detail about pathways and targeting, the utility of these applications has dramatically improved the drug development process for cancer research. Live animal imaging can be used in all stages of oncology drug development, from target identification through efficacy studies and disease phenotyping to the pharmacokinetic studies pre-Phase 1. Understanding a therapy's potential benefit from an early stage through detailed imaging applications can guide the evolution of a therapy and improve the likelihood of developing a successful drug candidate.

Oncology is one of the most prominent areas of scientific research, with more than $75 billion spent by the US government on cancer research over the past 30 years. Imaging applications are becoming increasingly important in oncology research as they are able to provide significantly more information at a lower cost to the researcher while using fewer animals. With a variety of imaging techniques available, it is most beneficial to utilize several modalities in a development process according to their relative strengths. Co-registering imaging data collected from multiple modalities can validate drug development and ultimately provide a more seamless path to the clinic.

Anatomical vs. Molecular Imaging

Live animal imaging methods are generally divided into anatomical and molecular techniques. The physical techniques like X-ray computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI) are characterized by exquisite spatial resolution. Molecular imaging modalities such as positron emission tomography (PET), single photon emission computed tomography (SPECT), or optical methods may have lower spatial resolution but have evolved to characterize and quantify biological processes at the cellular and sub-cellular level. For drug development, the insight into functional mechanisms gained from molecular imaging is essential, but a combination of methods using multimode detection (e.g., PET-CT) or co-registration post-acquisition (e.g., optical-MRI) can provide additional insight and ultimately form the basis of translation to the clinic.

Physical imaging methods require structural changes large enough to be detected. With a molecular technique, however, an imaging probe can be used to interact directly with the molecular target, or a reporter gene linked to target expression can be monitored at very low levels of expression—or combinations of the above.

While target validation provides the first application area, the major economic benefits can be seen in efficacy studies where the ability to model multiple parameters at once enables more cycles of compound optimization in a given time frame. Further down the development pipeline, pharmacokinetic studies can also be accelerated using animal imaging techniques. With reporter gene assays performed in vivo, results can be generated in a few hours, avoiding an extensive histopathology analysis and weeks of delay for an actionable result.

Co-registration of CT and fluorescence images in 3D. (Source: Caliper Life Sciences)



Reproducible Results

Studies performed non-invasively in the intact animal allow for repetitive and reproducible analysis over a time course. Repeatedly imaging the same animals in a longitudinal study allows researchers to achieve statistical significance with relatively few animal subjects and generate a mechanistic understanding of the biological response. The savings in time and animal handling are significant, and the researcher avoids having to sacrifice animals at every time point. With optical reporters, the method is not only sensitive, but can also be high-throughput and low cost. For oncology research in particular, transgenic tumor lines can be readily engineered with fluorescent or bioluminescent reporters to provide a high throughput platform and a low cost assay.

Fluorescence and Bioluminescence

Fluorescent and bioluminescent optical imaging have developed as sensitive, cost-effective methods for quantitative, noninvasive longitudinal studies monitoring tumorigenesis, metastasis, and responsiveness to anticancer agents in living animals. Fluorescence allows the visualization of both metabolically active and inactive cells in vivo, and also provides a convenient histological marker. Light emission requires excitation by an external light source. The typical approach is to genetically encode luciferase or fluorescent proteins (red fluorescent proteins work best) into tumor cells so that the molecular or cellular events can be visualized and tracked non-invasively during cancer disease progression.

Bioluminescence typically monitors metabolically active cells and requires interaction of the luciferase with injected luciferin and ATP. It can be exquisitely sensitive in the detection of labeled cells and can visualize a single cell subcutaneously. Both fluorescent and bioluminescent moieties can also be conjugated to endogenously injected targeting probes in order to detect cellular markers in vivo.

Orthotopic Oncology Models

Non-invasive, in vivo optical imaging using bioluminescent reporters enables an entire field of orthotopic oncology models. Compared to subcutaneous models of tumor development, orthotopic models can show more relevant host-tumor interaction with organ-specific growth environment and drug exposure, characteristic disease progression, metastatic potential, and response to therapy. Those differences reflect the greater biological relevance of the model. Orthotopic tumors are more likely to metastasize earlier, and metastatic progression contributes significantly to the survival time. Live animal imaging provides oncology researchers with means to explore orthotopic and spontaneous tumors that more closely represent natural tumor development.

Accelerating the Drug Discovery Process

Prostate tumor imaged using bioluminescence. (Source: Caliper Life Sciences)

With an appropriate biological model and an efficient imaging method, live animal studies can be used to screen compounds early in the development process, enabling additional cycles of optimization on successful drug candidates to reduce their risk of failure at a later, more costly stage. Getting compound into animals sooner allows researchers to more quickly identify risks. In addition, the increased speed of assays allows researchers to run additional chemistry and efficacy models before progressing to the next phase. A low-cost assay method in live animals, therefore, significantly accelerates the discovery process and improves the quality of the lead compounds being carried forward.

Monitoring Tumor Growth

Cancer metastases are the most lethal attributes of human malignancy and remain an ongoing therapeutic challenge for drug discovery. Using bioluminescent imaging, tumor development can be monitored, non-invasively, directly after implantation and micrometastases can be monitored from a minimal number of cells and followed throughout development concurrently with primary tumor growth.

From a practical perspective, bioluminescent imaging (BLI) can be used to randomize animals into experimental cohorts before establishing the treatment regimes. Animals can be monitored routinely from day one to follow development of the primary tumors—whatever their location—without the need for sacrifice, dissection or histopathology. By following the same animal longitudinally, the kinetics of metastatic burden can be easily monitored throughout treatment.

Drug treatment, regression and relapse can also be measured in the same cohort of animals, generating improved statistics from fewer animals. With BLI it is easy to measure the anti-tumor and anti-metastatic activity of a therapeutic intervention—even if the activity can not be detected by physical means.

Pathways and Mechanisms

Because BLI output depends on the presence of actively metabolizing cells it can be more sensitive in the detection of therapeutic impact than physical measurement of a tumor. Drug therapies that kill tumor cells will cause an immediate reduction in BLI, but if they do not cause shrinkage of the tumor they can be missed in screening. Optical imaging techniques also allow the exploration of underlying mechanisms of tumor growth, with models for the monitoring of hypoxia, apoptosis, angiogenesis, or gene regulation in vivo and in real time.

Bioluminescent reporters are commonly used to monitor VEGFR2 expression when angiogenesis is stimulated during tumor growth. The tumor itself may be expressing a fluorescent protein and fluorescent conjugates are commonly used to track specific tumor markers such as HER2 on the cell surface. So called "Active" dyes change their fluorescent emission when they are chemically modified in situ (e.g., cleaved by proteases), and with careful selection of their spectral properties, all of these optical signals can be imaged together to unravel the complex biological processes.

Three-Dimensional Data

Planar, two-dimensional imaging is an ideal tool early in drug discovery because it is low cost, high throughput, rapid to perform and quantitative for longitudinal studies. For additional insight into the disease process, or for absolute quantitation of a signal, an optical tomographic method can be used to generate three-dimensional data output. Both bioluminescence and fluorescence can be imaged in three dimensions and the reconstructed images can be co-registered with other imaging modalities. Reconstruction of BLI with CT, for example, might be critical in demonstrating a tumor metastasizing to bone. Co-registering fluorescence with MRI might be integral to developing a translational contrast agent for use in the clinic.

Conclusion

Access to live animal imaging has provided key results for judging the efficacy of many drugs in the clinic or in clinical trials. Live molecular imaging provides data consistent with results from physical measurements, and histology or anatomical imaging techniques such as X-ray or MRI while providing the least amount of disruption to normal biological processes. The robust, quantitative and high-throughput modality of optical imaging provides an ideal platform for pre-clinical development. Using optical imaging techniques, tumor development can be followed with a rigor that would be unfeasible using traditional sampling and histology techniques and can be more stringently evaluated for compound efficacy, providing additional validation and a direct path to the clinic.
n Stephen Oldfield received his PhD from Imperial College, London and has worked in various tool companies providing innovative technology for drug discovery and development.
Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Bringing the Cell Image into Focus

Nov 2

Improvements in transmission electron microscope (TEM) technology increase the power of this imaging tool for the study of cell biology.

Finding a Cure for Spinal Cord Injury with On-Demand LIMS

Oct 25

The Miami Project to Cure Paralysis finds an on-demand laboratory information management system (LIMS) helps to accelerate discovery in its HCS projects.

Saving Cells: Image Processing for Improved Viability, Part II: Iterative Deconvolution

Oct 25

3D light microscopy and deconvolution provide a means to investigate 3D structure, providing near-confocal quality images without the temporal requirements or potentially damaging phototoxicity associated with other 3D imaging technologies. This article is Part II in a series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part I focused on spectral unmixing.

Saving Cells: Image Processing for Improved Viability

Sep 22

This article is Part I of a two-part series regarding viability, resolution improvement, and measurement in fluorescence imaging. Part II will focus on deconvolution.

Selecting Robots for Use in Drug Discovery and Testing

Dec 6

Drug discovery and testing, with their need for speed, repeatability and verification, are ideally suited to benefit from robot automation. It is therefore not surprising that robots have been at the forefront of automation developments in both these areas.

HP Scalable Network Storage Systems for Life Sciences

Sep 13

Life sciences research today is advancing exponentially, each step bringing us closer to the realization of truly personalized medicine–preventive care and treatments designed specifically for each individual. In the near future, PCPGM healthcare researchers expect to be able to use predictive genetic testing to create custom treatment plans for individuals and deliver dramatic improvements over today’s one-size-fits-all approach. But research capabilities are only part of the equation; current storage and operating capacities must also evolve to accommodate ever-expanding amounts of data before the goal of personalized medicine can be realized.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.

Dec 19

Human hepatocellular carcinoma (HCC) is considered difficult to cure because its resistant to radio- and chemotherapy and high recurrence rate after curative liver resection. Epidermal growth factor receptor variant III (EGFRvIII) has shown to express in HCC...

Nutrients and the Pkh1/2 and Pkc1 protein kinases control mRNA decay and P-body assembly in yeast.

Dec 19

Regulated mRNA decay is essential for eukaryotic survival but the mechanisms for regulating global decay and coordinating it with growth, nutrient and environmental cues are not known. Here we show that a signal transduction pathway containing the Pkh1/Pkh2...

Kallikrein-5 promotes cleavage of desmoglein-1 and loss of cell-cell cohesion in oral squamous cell carcinoma.

Dec 19

Oral squamous cell carcinoma (OSCC) ranks among the top 8 causes of cancer death worldwide, with only a 60% 5-year survival rate, highlighting the need for discovery of novel biomarkers and therapeutic targets. We have previously reported that expression of a...

Nuclear choline acetyltransferase activates transcription of a high-affinity choline transporter.

Dec 19

Choline acetyltransferase (ChAT) synthesizes the neurotransmitter, acetylcholine (ACh), at cholinergic nerve terminals. ChAT contains nuclear localization signals (NLSs) and is also localized in the nuclei of neural and non-neuronal cells. Nuclear ChAT might...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: